Identifying miRNAs in multiple sclerosis gray matter lesions that correlate with atrophy measures

Abstract

Abstract Objective Multiple sclerosis (MS) is an inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS). Though MS was initially considered to be a white matter demyelinating disease, myelin loss in cortical gray matter has been reported in all disease stages. We previously identified microRNAs (miRNAs) in white matter lesions (WMLs) that are detected in serum from MS patients. However, miRNA expression profiles in gray matter lesions (GMLs) from progressive MS brains are understudied. Methods We used a combination of global miRNAs and gene expression profiling of GMLs and independent validation using real‐time quantitative polymerase chain reaction (RT‐qPCR), immuno‐in situ hybridization, and immunohistochemistry. Results Compared to matched myelinated gray matter (GM) regions, we identified 82 miRNAs in GMLs, of which 10 were significantly upregulated and 17 were significantly downregulated. Among these 82 miRNAs, 13 were also detected in serum and importantly were associated with brain atrophy in MS patients. The predicted target mRNAs of these miRNAs belonged to pathways associated with axonal guidance, TGF‐β signaling, and FOXO signaling. Further, using state‐of‐the‐art human protein–protein interactome network analysis, we mapped the four key GM atrophy‐associated miRNAs (hsa‐miR‐149*, hsa‐miR‐20a, hsa‐miR‐29c, and hsa‐miR‐25) to their target mRNAs that were also changed in GMLs. Interpretation Our study identifies miRNAs altered in GMLs in progressive MS brains that correlate with atrophy measures. As these miRNAs were also detected in sera of MS patients, these could act as markers of GML demyelination in MS.